New paper w/Paul Martin & Jin Ding: “Why is the pharmaceutical industry investing in targeted therapies? The emergence of “premium pharma" | How #orphandrugs #ATMPs #TargetedTherapies reshape #BioPharmaInnovation #HTA sciencedirect.com/science/article/pii/S0277953625012195 @sheffielduni.bsky.social